VYTRUS BIOTECH EO -01 (V5P) - Total Liabilities

Latest as of December 2025: €4.35 Million EUR ≈ $5.09 Million USD

Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore V5P cash generation efficiency to assess how effectively this company generates cash.

VYTRUS BIOTECH EO -01 - Total Liabilities Trend (2021–2025)

This chart illustrates how VYTRUS BIOTECH EO -01's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are VYTRUS BIOTECH EO -01's assets to evaluate the company's liquid asset resilience ratio.

VYTRUS BIOTECH EO -01 Competitors by Total Liabilities

The table below lists competitors of VYTRUS BIOTECH EO -01 ranked by their total liabilities.

Company Country Total Liabilities
Evertop Wire Cable Corp
TW:1616
Taiwan NT$2.06 Billion
Interactive Digital Technologies
TWO:6486
Taiwan NT$1.53 Billion
Cheryong Industrial Co.Ltd
KQ:147830
Korea ₩13.83 Billion
Salasar Techno Engineering Limited
NSE:SALASAR
India Rs10.35 Billion
Corpovael S.A.B. de C.V
MX:CADUA
Mexico MX$6.43 Billion
Generation Mining Ltd
TO:GENM
Canada CA$69.62 Million
Fate Therapeutics Inc
NASDAQ:FATE
USA $109.61 Million
The Pinkfong Company
KQ:403850
Korea ₩19.70 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down VYTRUS BIOTECH EO -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see V5P market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how VYTRUS BIOTECH EO -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for VYTRUS BIOTECH EO -01 (2021–2025)

The table below shows the annual total liabilities of VYTRUS BIOTECH EO -01 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €4.35 Million
≈ $5.09 Million
+13.44%
2024-12-31 €3.84 Million
≈ $4.49 Million
-4.57%
2023-12-31 €4.02 Million
≈ $4.70 Million
+23.76%
2022-12-31 €3.25 Million
≈ $3.80 Million
+10.85%
2021-12-31 €2.93 Million
≈ $3.43 Million
--

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$138.40 Million
€118.38 Million EUR
Market Cap Rank
#18237 Global
#1705 in Germany
Share Price
€15.75
Change (1 day)
-4.55%
52-Week Range
€3.02 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more